FMP
CONMED Corporation
CNMD
NYSE
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
57.08 USD
-0.67 (-1.17%)
Zacks Investment Research
Aug 19, 2024
ARRY, BSM and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2024.
Zacks Investment Research
Aug 15, 2024
ARCO, CNMD and CVS have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2024.
Zacks Investment Research
Aug 5, 2024
AMX, CNH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2024.
Zacks Investment Research
Aug 1, 2024
CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.
Zacks Investment Research
Jul 31, 2024
Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research
Jul 31, 2024
Conmed (CNMD) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.83 per share a year ago.
Zacks Investment Research
Jul 24, 2024
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research
Jun 27, 2024
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
InvestorPlace
May 19, 2024
Following the so-called “smart money” is often a wise strategy for retail investors. Most individual investors fail to outperform the broader market over the long-run.
Zacks Investment Research
Apr 25, 2024
CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.